English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background DNA methylation is involved in pathogenesis of acute myeloid leukemia (AML). N6-methyladenosine (m6A) modification of mRNA, mediated by methyltransferase-like 3 ( METTL3 ), is one of the well-identified mRNA modifiers associated with the pathogenesis of AML. High level of  METTL3  mRNA is detected in AML cells, thus can be a potential target therapy for AML. This is a preliminary study that aimed at measuring  METTL3  mRNA expression level in de novo AML patients and correlating it with clinicopathological, laboratory and prognostic markers.  METTL3  expression was analyzed by quantitative reverse transcription polymerase chain reaction in 40 newly diagnosed AML adults and was re-measured in the 2nd month of chemotherapy. Patients were followed up for periods up to 6 months post-induction therapy. Results METTL3  expression was found to be significantly upregulated in AML patients compared to control subjects ( p  &lt; 0.001).  METTL3  gene was significantly expressed among non-responders compared to responders ( p  &lt; 0.001). A cutoff value was assigned for normalized  METTL3  values to categorize AML patients according to response to therapy. Statistically significant association was observed between high pretreatment normalized  METTL3  gene level and failure to attain complete remission at 2nd, 4th and 6th month following therapy ( p  = 0.01, 0.02 and 0.003, respectively) .  However, insignificant correlation was found between pretreatment normalized  METTL3  gene level and event free survival or clinicopathological prognostic factors. Conclusion METTL3  is overexpressed in AML patients and is associated with adverse prognostic effect and failure to attain hematological remission within 6 months post-induction therapy.

Methyltransferase-like 3 gene (METTL3) expression and prognostic impact in acute myeloid leukemia patients